ETHRIS: Funding, Investors & Team (Sep 2026)
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
ETHRIS has raised $42.6M across 3 funding rounds on record, the most recent an undisclosed round of $11.3M announced in May 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ETHRIS Company Profile and Key Stats
Latest funding round on record: May 2025.
ETHRIS Funding Rounds
ETHRIS raised $26.3M in a Series B announced in Feb 2022.
2.3 years later, an undisclosed round of $5.0M was announced in Jun 2024.
11 months later, an undisclosed round of $11.3M was announced in May 2025.
ETHRIS Founders and Leadership Team
Contact details for the ETHRIS team: 1 of 3 have an email address on file.
Start 14-day free trial →ETHRIS Funding Compared to Other Biotechnology Startups
ETHRIS' latest round of $11.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ETHRIS in Biotechnology and Planegg
Companies Similar to ETHRIS
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
ETHRIS Funding FAQs
What does ETHRIS do?
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
How much funding has ETHRIS raised?
ETHRIS has raised $42.6M across 3 rounds on record. The most recent is an undisclosed round of $11.3M announced in May 2025.
When did ETHRIS last raise funding?
ETHRIS' most recent funding round on record is an undisclosed round of $11.3M, announced in May 2025.
Who founded ETHRIS?
FundedIQ lists Pd Carsten Rudolph (Founder), Prof Christian Plank (Founder) at ETHRIS.
Who is the CEO of ETHRIS?
Carsten Rudolph is listed as CEO at ETHRIS.
Where is ETHRIS headquartered?
ETHRIS is based in Planegg, Bayern, Germany.
How many employees does ETHRIS have?
ETHRIS is in the 101-250 employee band.
How does ETHRIS' funding compare to other Biotechnology startups?
ETHRIS' latest round of $11.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ETHRIS Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ETHRIS is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.